-
-
-
-
-
-
-
ChemoCentryx Announces Filing of Amendment to NDA Submission and Extension of the PDUFA Review Period for Avacopan in the Treatment of ANCA-Associated Vasculitis
-
-
-
-
-
-
-
ChemoCentryx Announces Results of FDA Advisory Committee Meeting on Avacopan in ANCA-Associated Vasculitis
-
-
-
-
-
-
-
ChemoCentryx Announces FDA Acceptance of the Avacopan New Drug Application (NDA) for the Treatment of ANCA-Associated Vasculitis
-
15,627 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

